| Literature DB >> 28417300 |
Yue Yin1, Zhiwen Xu1,2, Xiaowan Liu1, Ping Li1, Fan Yang1, Jun Zhao1, Yi Fan1, Xiangang Sun1, Ling Zhu3,4.
Abstract
Emerging pseudorabies virus (PRV) variant has led to frequent outbreaks of PRV infection among Bartha-K61-vaccinated swine population in Chinese swine farms and caused high mortality in pigs of all age since late 2011. Here, we generated a gE/gI-deleted PRV (rPRVXJ-delgI/gE-EGFP) based on PRV variant strain (PRV-XJ) through homologous DNA recombination. Compared to parental strain, rPRVXJ-delgI/gE-EGFP showed similar growth kinetics in vitro. Its safety and immunogenicity were evaluated in weaned piglets. Our results showed that piglets immunized with rPRVXJ-delgI/gE-EGFP did not exhibit any clinical symptoms, and a high level of gB-specific antibody was detected. After lethal challenge with variant PRV (PRV-FJ strain), all vaccinated piglets survived without showing any clinical symptoms except slight fever within 7 days post-challenge. In unvaccinated piglets, typical clinical symptoms of pseudorabies were observed, and the piglets were all died at 5 days post-challenge. These results indicated that a live rPRVXJ-delgI/gE-EGFP vaccine could be a maker vaccine candidate to control the currently epidemic pseudorabies in China.Entities:
Keywords: Efficacy; Marker vaccine; PRV variant; Safety; gE/gI deletion
Mesh:
Substances:
Year: 2017 PMID: 28417300 DOI: 10.1007/s11262-017-1454-y
Source DB: PubMed Journal: Virus Genes ISSN: 0920-8569 Impact factor: 2.332